IFNG and cancer: In the absence of IFNγ treatment, TP53 stimulation increases the major histocompatibility complex I (MHCI)-antigen presentation in cancer cells, which harbor wild-type TP53 through the activation of the endoplasmic reticulum aminopeptidase ERAP1 (27).